Effect of Simvastatin on Arterial Stiffness in Patients with Statin Myalgia

Table 2

Plasma lipid changes by drug assignment and myalgia status^a,b.

	Nonmyalgic sample ()		Myalgic sample ()
	Simvastatin	Placebo	Simvastatin	Placebo
ΔTC, mmol/L	−1.50 ± 0.84	−0.04 ± 0.58	−1.67 ± 0.61	−0.03 ± 0.70
ΔLDL-C, mmol/L	−1.44 ± 0.67	−0.01 ± 0.50	−1.51 ± 0.60	−0.14 ± 0.60
ΔHDL-C, mmol/L	0.08 ± 0.18	−0.01 ± 0.15	0.04 ± 0.18	0.02 ± 0.14
ΔTG, mmol/L	−0.65 ± 2.47	0.04 ± 1.66	−1.00 ± 2.50	0.48 ± 2.73

^aData are means ± SD; Δ = absolute change from before to after the treatment intervention.
^bLDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. from baseline. There were no differences () between nonmyalgic and myalgic participants within a treatment group.